Elanco Animal Health (ELAN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $13.39B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elanco Animal Health (ELAN) Stock Forecast
Analysts expect Elanco Animal Health (ELAN) to earn $1.18 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.19B. Of 16 analysts, 13 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.94, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 81% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 25.0% |
| Buy | 9 | 56.3% |
| Hold | 3 | 18.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.3% and revenue estimates rise 5.0%.
- Fiscal year ending Dec 31, 2026
- $1.18
- EPS consensus, revenue $5.19B
- Fiscal year ending Dec 31, 2027
- $1.29
- EPS consensus, revenue $5.45B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.18 | $1.16 to $1.20 | 10 | $5.19B | $5.16B to $5.21B | 10 |
| Dec 31, 2027 | $1.29 | $1.22 to $1.34 | 14 | $5.45B | $5.31B to $5.53B | 12 |
Quarterly Estimates
The EPS consensus rises from $0.18 for the quarter ending Dec 31, 2026 to $0.44 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.18 | $0.14 to $0.20 | 15 | $1.22B | $1.16B to $1.28B | 13 |
| Mar 31, 2027 | $0.44 | $0.42 to $0.46 | 8 | $1.43B | $1.42B to $1.45B | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 7 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 6 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.4% from $1.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.18 | $1.13 | $1.14 | $1.13 | $1.13 | +5.1% |
| Fiscal year ending Dec 31, 2027 | $1.29 | $1.27 | $1.28 | $1.28 | $1.26 | +2.1% |
| Quarter ending Mar 31, 2027 | $0.44 | $0.44 | $0.44 | $0.44 | $0.44 | -0.5% |
Frequently Asked Questions About ELAN
What is the ELAN stock forecast?
Consensus analyst estimates put Elanco Animal Health's EPS at $1.18 for the fiscal year ending Dec 31, 2026, on revenue of $5.19B. The consensus rating from 16 analysts is Buy.
How do analysts rate ELAN stock?
Of 16 analysts covering Elanco Animal Health, 4 rate it Strong Buy, 9 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ELAN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.18, with estimates from $1.16 to $1.20 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.29, with estimates from $1.22 to $1.34 from 14 analysts.
What revenue do analysts expect from Elanco Animal Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.19B, with estimates from $5.16B to $5.21B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.45B, with estimates from $5.31B to $5.53B.
How many analysts cover ELAN?
16 analysts rate Elanco Animal Health stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ELAN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors